Vladimir Chupakhin

Vladimir Chupakhin has extensive experience in the field of chemoinformatics and computational chemistry. Vladimir has worked as a Principal Scientist at Simulations Plus, Inc. since 2023. Prior to that, they were a Lead Computational Chemist at ChAI42, where they supported cheminformatics and computational chemistry pipelines in a startup. Vladimir also assisted in the preparation of pitch decks and aligned machine learning solutions with biotech R&D pipelines.

From 2021 to 2023, they served as a Principal Scientist at Cellarity. Before that, they worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as a Senior Scientist, where they focused on machine learning for small molecule drug design and chemogenomics models.

In 2010, they were a Postdoctoral Fellow at Université de Strasbourg, working on a joint project in chemoinformatics and structural chemogenomics. Vladimir also worked as a Research Associate at IPAC RAS, where they were involved in computer-aided drug design projects.

Earlier in their career, they worked as a Scientist at GeneGo, supporting the development of MetaDrug, a SaaS platform for system pharmacology research. Vladimir also completed their PhD at Moscow State University, focusing on computational design of ligands for GABAA receptor based on homology and QSAR models.

Vladimir Chupakhin completed their Master's degree in Pharmaceutical Chemistry at Chuvash State University from 1998 to 2003. Vladimir then pursued a PhD in Molecular informatics at Moscow State University from 2003 to 2010. Following this, they engaged in postdoctoral research at the University of Strasbourg from 2010 to 2011. In terms of additional certifications, they obtained an Executive Data Science Specialization from Coursera Course Certificates in 2016. Additionally, they received certifications in the fields of Leadership in an Exponentially Changing World from the MIT Sloan School of Management in 2022, and Ethical and Social Challenges of Genomic and Precision Medicine from Coursera Verified Certificates in 2014. Moreover, in 2023, they obtained a certification in Free Energy Calculations for Drug Design with FEP+ from Schrödinger.